Kantonsspital St.Gallen
anmelden

Publikationen

Markus Joerger

Titel  
 
Klopp-Schulze L, Joerger M, Wicha S G, Ter Heine R, Csajka C, Parra-Guillen Z P, Kloft C. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. Clin Pharmacokinet 2018; 57:229-242.
   
Siano M, Jarisch N, Joerger M, Espeli V. Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer. Anticancer Res 2018; 38:3725-3729.
   
Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 2018; 96:6-16.
   
Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné A S, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé V O, Van Calster B, Guchelaar H J. Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. Clin Cancer Res 2018; 24:2312-2318.
   
Behrend H, Lengnick H, Zdravkovic V, Ladurner A, Rudin D, Erschbamer M, Joerger M, Kuster M. Vitamin C demand is increased after total knee arthroplasty: a double-blind placebo-controlled-randomized study. Knee Surg Sports Traumatol Arthrosc 2018;.
   
Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann C J, Allegrini S, Catapano C V, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C, Swiss Group for Clinical Cancer Research (SAKK) . Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Invest New Drugs 2017; 35:766-772.
   
Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. J Transl Med 2017; 15:66.
   
Gachechiladze M, Škarda J, Kolek V, Grygárková I, Langová K, Bouchal J, Kolář Z, Baty F, Stahel R, Weder W, Soltermann A, Joerger M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. Lung Cancer 2017; 105:31-38.
   
Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, Amstutz U, Largiader C R. Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. Clin Pharmacol Ther 2017; 102:796-804.
   
Gachechiladze M, Škarda J, Soltermann A, Joerger M. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies. Int J Cancer 2017; 141:1286-1294.
   
Joerger M, Kraff S, Jaehde U, Hilger R A, Courtney J B, Cline D J, Jog S, Baburina I, Miller M C, Salamone S J. Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM). Ther Drug Monit 2017; 39:617-624.
   
Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen Z P. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. J Pharmacol Exp Ther 2017; 362:347-358.
   
Parra-Guillen Z P, Berger P B, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, Gillessen Sommer S, Krähenbühl S, Kloft C, Joerger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.
   
Warschkow R, cerny t, Schmied B, Gueller U, Thürlimann B, Joerger M. A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction. Br J Cancer 2016; 115:80-4.
   
Klopp-Schulze L, Joerger M, Wicha S G, Parra-Guillen Z P, Kloft C. Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
. Int J Clin Pharmacol Ther 2016;.
   
Warschkow R, Gueller U, Tarantino I, cerny t, Schmied B, Thürlimann B, Joerger M. Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis. Ann Surg 2016; 263:1188-98.
   
Baty F, Joerger M, Früh M, Brutsche M. 61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2016; 11:S81.
   
Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, cerny t, Joerger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer 2016; 100:38-44.
   
Hager S, Ackermann C J, Joerger M, Gillessen S, Omlin A. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol 2016; 27:975-84.
   
Meulendijks D, Rozeman E A, Cats A, Sikorska K, Joerger M, Deenen M J, Beijnen J H, Schellens J H M. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. Pharmacogenomics J 2016;.
   
Hamzic S, Wenger N, Froehlich T K, Joerger M, Aebi S, Largiadèr C R, Amstutz U. The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics J 2016;.
   
Crombag M R B S, Joerger M, Thürlimann B, Schellens J H M, Beijnen J H, Huitema A D R. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8:.
   
Shao S, Guo T, Gross V, Lazarev A, Koh C C, Gillessen Sommer S, Joerger M, Jochum W, Aebersold R. Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology. J Proteome Res 2016; 15:1821-9.
   
Joerger M, Finn S P, Cuffe S, Byrne A T, Gray S G. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. Expert Opin Ther Targets 2016; 20:1339-1356.
   
Joerger M, von Pawel J, Kraff S, Fischer J R, Eberhardt W, Gauler T C, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp H G, Behringer D M, Ko Y D, Hilger R A, Roessler M, Kloft C, Henrich A, Moritz B, Miller M C, Salamone S J, Jaehde U. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2016; 27:1895-902.
   
Shao S, Guo T, Koh C C, Gillessen Sommer S, Joerger M, Jochum W, Aebersold R. Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry. Proteomics 2015; 15:3711-21.
   
Joerger M, van Schaik R H N, Becker M L, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen Sommer S, Rothermundt C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 2015;.
   
Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, cerny t, Beijnen J H, Schellens J H M. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 2015; 75:763-72.
   
Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft H S, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey U J M. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2015; 101:346-55.
   
Kraff S, Nieuweboer A J M, Mathijssen R H J, Baty F, de Graan A J, van Schaik R H N, Jaehde U, Joerger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol 2015;.
   
Guo T, Kouvonen P, Koh C C, Gillet L C, Wolski W E, Röst H L, Rosenberger G, Collins B C, Blum L C, Gillessen Sommer S, Joerger M, Jochum W, Aebersold R. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med 2015; 21:407-13.
   
Froehlich T K, Amstutz U, Aebi S, Joerger M, Largiadèr C R. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2014; 136:730-9.
   
Joerger M, Baty F, Früh M, Droege C, Stahel R A, Betticher D C, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85:306-13.
   
Joerger M. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol 2014;1-12.
   
Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, cerny t. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 2014; 70:719-25.
   
Büchel B, Sistonen J, Joerger M, Aebi Y, Schürch S, Largiadèr C R. Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients. Clin Chem Lab Med 2013; 51:1681-8.
   
Früh M, Besrour H, Gillessen Sommer S, Joerger M, Hitz F, Savidan A, cerny t, Ess S. Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. Chemotherapy 2013; 59:42-50.
   
Joerger M, Thürlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013; 13:165-78.
   
Joerger M, Huitema A D R, Koeberle D, Rosing H, Beijnen J H, Hitz F, cerny t, Schellens J H M, Gillessen Sommer S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol 2013; 73:113-24.
   
Joerger M. [Role of individualized dosing in oncology: are we there yet?]. Praxis (Bern 1994) 2013; 103:33-9.
   
Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
   
Joerger M, Ess S, Dehler S, Savidan A, Bouchardy C, Frick H, Konzelmann I, Thürlimann B. A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss Med Wkly 2012; 142:w13571.
   
Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J 2012; 14:119-32.
   
Büchel B, Joerger M, Schürch S, Largiader C. Characterization of endogenous UH2/U metabolite ratios in cancer patients receiving 5-fluorouracil chemotherapy. Biomed Chromatogr 2012;.
   
Büchel B, Joerger M, Schürch S, Largiader C. Assessment of metabolic 5,6-dihydourcail/uracil ratios as predictors of 5-fluorouracil-related toxicities. 2012; Clinical Chemistry Annual Conference:.
   
Joerger M, Matter-Walstra K, Früh M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis. Ann Oncol 2012; 22:567-574.
   
Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, Ess S. A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer. Clin Breast Cancer 2012; 12:102-9.
   
Joerger M, Kraff S, Huitema A D R, Feiss G, Moritz B, Schellens J H M, Beijnen J H, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012; 51:607-17.
   
Joerger M, Huitema A D R, Illerhaus G, Ferreri A J M. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma 2012; 53:1867-75.
   
Joerger M, Ferreri A J M, Krähenbühl S, Schellens J H M, cerny t, Zucca E, Huitema A D R. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 2012; 73:240-7.
   
hochstrasser a, Benz G, Joerger M, templeton a, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy 2012; 58:84-88.
   
Joerger M, Huober J. Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res 2012; 192:197-223.
   
Joerger M, Thürlimann B, Savidan A, Frick H, Rageth C, Lütolf U, Vlastos G, Bouchardy C, Konzelmann I, Bordoni A, Probst-Hensch N, Jundt G, Ess S. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study. J Geriatr Oncol 2012; 4:39-47.
   
Joerger M, Wilkins J, Fagagnini S, Baldinger R, Brenneisen R, Schneider U, Goldman B, Weber M. Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metab Lett 2012; 6:102-8.
   
Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health 2011; 15:65-71.
   
adamina m, Joerger M. Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011; 7:201-211.
   
Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, Ess S. A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer. Clin Breast Cancer 2011;.
   
Joerger M. Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011; 7:201-11.
   
Joerger M, deJong D, Burylo A, Burgers J A, Baas P, Huitema A D R, Beijnen J H, Schellens J H M. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 2011; 74:310-7.
   
Joerger M, Burgers S A, Baas P, Smit E F, Haitjema T J, Bard M P L, Doodeman V D, Smits P H M, Vincent A, Huitema A D R, Beijnen J H, Schellens J H M. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2011; 118:2466-75.
   
Joerger M, Huitema A D R, Illerhaus G, Ferreri A J M. High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?. Leuk Lymphoma 2011; 52:1825-7.
   
Joerger M, Burgers J A, Baas P, Doodeman V D, Smits P H M, Jansen R S, Vainchtein L D, Rosing H, Huitema A D R, Beijnen J H, Schellens J H M. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011; 69:25-33.
   
Joerger M, Huitema A D R, Krähenbühl S, Schellens J H M, cerny t, Reni M, Zucca E, Cavalli F, Ferreri A J M. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
   
Joerger M, Riesen W F, Thürlimann B. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer. J Oncol Pharm Pract 2010;.
   
Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2010; 2:293-301.
   
Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
   
Buikhuisen W A, Burgers J A, Vincent A D, Schellens J H M, Beijnen J H, Smit E F, Joerger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. J Clin Oncol 2010; 28:e482-3; author reply e484.
   
Joerger M, Omlin A, cerny t, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Current drug targets 2010; 11:37-47.
   
Joerger M, templeton a, koeberle d, Engler H, Riesen W F, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol 2010;.
   
Ess S, Joerger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thürlimann B. Predictors of state-of-the-art management of early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.
   
Joerger M, Thürlimann B, huober j. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Ann Oncol 2010; 22:17-23.
   
Joerger M. Neue Optionen endokriner Therapieindividualisierung? Pharmakogenetik bei Brustkrebs : Leading Opinions. Medizin für die Frau 2009; 1:28-30.
   
templeton a, Thürlimann B, Joerger M. Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen. Schweizer Krebsbulletin 2009;114-117.
   
Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review. Gerontology 2009;.
   
Smit E F, Burgers S A, Biesma B, Smit H J M, Eppinga P, Dingemans A M C, Joerger M, Schellens J H, Vincent A, van Zandwijk N, Groen H J M. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:2038-45.
   
Joerger M, Senn H J, Thürlimann B. St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy. magazine of european medical oncology 2009; 2:229-231.
   
Joerger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we stand?. Breast 2009; 18 Suppl 3:S78-82.
   
Joerger M, nuessli d, Henz S, Zaunbauer W, cerny t, Cogliatti S B, Gillessen Sommer S. CT-diagnosed mesenteric alterations in patients with non-Hodgkin's lymphoma: a population-based study. Onkologie 2008; 31:514-9.
   
Ribi K, Bernhard J, Schuller J C, Weder W, Bodis S, Joerger M, Betticher D, Schmid R A, Stupp R, Ris H B, Stahel R A, Swiss Group for Clinical Cancer Research SAKK . Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404.
   
Greuter S, Joerger M, koeberle d. Adjuvante Therapie des Kolonkarzinoms. Onkologie 2007; 3:20-24.
   
von Rohr L, Klaeser B, Joerger M, Kluckert T, cerny t, Gillessen Sommer S. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie 2007; 30:320-3.
   
Rohr L, Klaeser B, Joerger M, Kluckert J T, cerny t, Gillessen Sommer S. Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis. Onkologie 2007;320-323.
   
Joerger M, Huitema A D R, Huizing M T, Willemse P H B, de Graeff A, Rosing H, Schellens J H M, Beijnen J H, Vermorken J B. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. British journal of clinical pharmacology 2007; 64:622-33.
   
Joerger M, Huitema A D R, Richel D J, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J B, Strocchi E, Martoni A, Sorio R, Sleeboom H P, Izquierdo M A, Jodrell D I, Calvert H, Boddy A V, Hollema H, Féty R, Van der Vijgh W J F, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers A H G J, Twelves C, Beijnen J H, Schellens J H M. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clinical cancer research : an official journal of the American Association for Cancer Research 2007; 13:6410-8.
   
Joerger M, Kuhn M. Probleme langwirkender Betamimetika bei Asthma. Pharma-Kritik 2007; 29:.
   
Joerger M, Huitema A D R, Richel D J, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J B, Strocchi E, Martoni A, Sorio R, Sleeboom H P, Izquierdo M A, Jodrell D I, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers A H G J, Twelves C, Beijnen J H, Schellens J H M, EORTC-PAMM-NDDG . Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clinical pharmacokinetics 2007; 46:1051-68.
   
Jermann M, Stahel R A, Salzberg M, cerny t, Joerger M, Gillessen Sommer S, Morant R, Egli F, Rhyner K, Bauer J A, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy and pharmacology 2006; 57:533-9.
   
Sparidans R W, Bosch T M, Joerger M, Schellens J H M, Beijnen J H. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006; 839:45-53.
   
Joerger M, Huitema A D R, van den Bongard H J G D, Baas P, Schornagel J H, Schellens J H M, Beijnen J H. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. British journal of clinical pharmacology 2006; 62:71-80.
   
Brouwers E E M, Tibben M M, Rosing H, Hillebrand M J X, Joerger M, Schellens J H M, Beijnen J H. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. Journal of mass spectrometry : JMS 2006; 41:1186-94.
   
Joerger M, Huitema A D R, Boogerd W, van der Sande J J, Schellens J H M, Beijnen J H. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic & clinical pharmacology & toxicology 2006; 99:133-40.
   
Joerger M, Huitema A D R, van den Bongard D H J G, Schellens J H M, Beijnen J H. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2006; 12:2150-7.
   
Joerger M, Bosch T M, Doodeman V D, Beijnen J H, Smits P H M, Schellens J H M. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. European journal of clinical pharmacology 2006; 62:681-4.
   
Brouwers E E M, Tibben M M, Joerger M, van Tellingen O, Rosing H, Schellens J H M, Beijnen J H. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and bioanalytical chemistry 2005; 382:1484-90.
   
Wuermli L, Joerger M, Henz S, Schmid H P, Riesen W F, Thomas G, Krek W, cerny t, Gillessen Sommer S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate cancer and prostatic diseases 2005; 8:316-20.
   
Würmli L, Joerger M, Henz S, Schmid H P, Riesen W F, Thomas G, Krek W, cerny t, Gillessen Sommer S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005; 8:316-320.
   
Joerger M, koeberle d, Neumann H P H, Gillessen Sommer S. Von Hippel-Lindau disease--a rare disease important to recognize. Onkologie 2005; 28:159-63.
   
Diethelm M, Joerger M. Letale Polypharmazie bei einem Hypertoniker - Erwiderung. Deutsche medizinische Wochenschrift (1946) 2005; 130:413-414.
   
Joerger M, Huitema A D R, Meenhorst P L, Schellens J H M, Beijnen J H. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer chemotherapy and pharmacology 2005; 55:488-96.
   
Dedes K J, Szucs T D, Bodis S, Joerger M, Lowy A, Russi E W, Steinert H C, Weder W, Stahel R A. Management and costs of treating lung cancer patients in a university hospital. PharmacoEconomics 2004; 22:435-44.
   
 
Seite 1 von 2